(S)-1-cyclopropyl-1,4-dihydro-7-[2-(N,N-dimethylaminomethyl)morpholino]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (S)-1-cyclopropyl-1,4-dihydro-7-[2-(N,N-dimethylaminomethyl)morpholino]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
• 英文别名: 1-Cyclopropyl-7-[(2S)-2-[(dimethylamino)methyl]morpholin-4-YL]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
• 化学式: C₂₁H₂₆FN₃O₅
• 分子量: 419.453
• InChiKey: HPXHHPSHSQYSGC-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  82.6
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (4-苄基-1,4-氧杂-2-基)甲胺 在 palladium on activated charcoal 甲酸 、 三乙胺 、 肼 作用下， 生成 (S)-1-cyclopropyl-1,4-dihydro-7-[2-(N,N-dimethylaminomethyl)morpholino]-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents

  摘要：

  A series of the titled compounds was synthesized and tested for anti-Helicobacter pylori activities. We discovered Y-34867 having the most potent activity against Helicobacter pylori among the quinolones tested along with high photostability. Furthermore, Y-34867 showed an excellent therapeutic effect in the experimental Helicobacter pylori infected Mongolian gerbil model. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00390-4

文献信息

• PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ATTRIBUTABLE TO INFECTION WITH HELICOBACTERS
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：EP0995746A1

  公开（公告）日：2000-04-26

  The present invention relates to an agent for the prophylaxis and treatment of diseases caused by Helicobacter infections, which comprises (S)-1-cyclopropyl-1,4-dihydro-7-[2-(N,N-dimethylaminomethyl)morpholino]-6-fluoro-8-methoxy-4-oxoguinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof. The prophylactic and therapeutic agent of the present invention is effective even when used alone in a small dose for a short time, is almost free of problematic side effects such as tolerance and diarrhea, and is low toxic and capable of safe and ensured bacterial eradication. It is useful for the prophylaxis and treatment of diseases caused by Helicobacter infections, particularly, gastritis, gastric ulcer, duodenal ulcer, malignant lymphoma and gastric cancer.

  本发明涉及一种用于预防和治疗由螺旋杆菌感染引起的疾病的药剂，它包括(S)-1-环丙基-1,4-二氢-7-[2-(N,N-二甲基氨基甲基)吗啉基]-6-氟-8-甲氧基-4-氧代谷氨酰胺-3-羧酸或其药学上可接受的盐。本发明的预防和治疗药物即使在短时间内小剂量单独使用也有效，几乎没有耐受性和腹泻等副作用问题，而且毒性低，能够安全地确保根除细菌。它可用于预防和治疗由螺旋杆菌感染引起的疾病，特别是胃炎、胃溃疡、十二指肠溃疡、恶性淋巴瘤和胃癌。
• US6221864B1
  申请人：——

  公开号：US6221864B1

  公开（公告）日：2001-04-24
• [EN] PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ATTRIBUTABLE TO INFECTION WITH HELICOBACTERS<br/>[FR] AGENT PROPHYLACTIQUE OU THERAPEUTIQUE CONTRE DES MALADIES ATTRIBUABLES A UNE INFECTION PAR DES HELICOBACTERS
  申请人：YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD.

  公开号：WO1998058928A1

  公开（公告）日：1998-12-30

  (EN) A prophylactic or therapeutic agent for diseases attributable to infection with helicobacters, characterized by containing (S)-1-cyclopropyl -1,4-dihydro-7- [2-(N,N-dimethylaminomethyl) morpholino]-6-fluoro-8- methoxy-4-oxoquinoline -3-carboxylic acid or pharmaceutically acceptable salts thereof. The agent is efficaceous as a single active ingredient preparation at a low dose in administration for a short period of time, is substantially free from unfavorable side effects such as tolerance and diarrhea, has low toxicity, can safely and surely remove bacteria, and is useful for prevention and treatment of diseases attributable to infection with helicobacters, such as gastritis, gastric ulcer, duodenal ulcer, malignant lymphona, and stomach cancer.(FR) Agent prophylactique ou thérapeutique contre des maladies attribuables à une infection par des hélicobacters, caractérisé par le fait qu'il contient acide (S)-1-cyclopropyle -1,4-dihydro-7- [2-(N,N-diméthylaminométhyl) morpholino]-6-fluoro-8- méthoxy-4-oxoquinoléine -3-carboxylique ou certains de ses sels acceptables sur le plan pharmaceutique. Cet agent est efficace sous forme de préparation contenant un seul ingrédient actif à faible dose administrée pendant une durée limitée, ne présente pratiquement aucun effet secondaire indésirable, tel que la tolérance ou la diarrhée, possède une toxicité basse, peut supprimer les bactéries de façon sûre et sans danger et est utile pour la prophylaxie et le traitement de maladies pouvant être attribuées à l'infection par des hélicobacters, telles que la gastrite, l'ulcère de l'estomac, l'ulcère du duodénum, le lymphome et le cancer de l'estomac.